UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy FTC sues to block two 'anticompetitive' hospital mergers in Utah and New Jersey Arise, Sir Soriot! AstraZeneca's chief knighted in honor of pharma's COVID battle 'The Top Line' podcast: COVID therapies dominate 2021's top-selling drugs, raising the curtain on ASCO 2022, plus this week's headlines Ashish Jha: COVID-19 vaccines for kids 5 and under could start as soon as June 21 ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter? After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy Medicare hospital trust fund to run out of money in 2028, trustees say Good news or bad news? FDA delays decision for Amylyx's ALS drug—and shares rise BD launches advanced flow cytometry system that sorts cells based on their inner workings Featured Story | By Annalee Armstrong Eyeing a rivalry with Roche and a new cancer asset slated to hit the markets next year, Bristol Myers Squibb is picking up Turning Point Therapeutics in a $4.1 billion deal. read more |
| |
|---|
|
| | Biotech got the world back on track. Now, we’re getting back together, and what happens next is Limitless. #BIO2022 |
Top Stories By Dave Muoio A five-hospital acquisition between HCA Healthcare and Steward Health Care as well as a merger between RWJBarnabas Health and Saint Peter's Healthcare System are on the federal regulator's chopping block. read more By Ben Adams AstraZeneca’s CEO Pascal Soriot has been knighted in the United Kingdom as a recognition of the U.K. pharma’s work on the COVID shot, Vaxzevria. read more By Teresa Carey This week on "The Top Line," we discuss our special report on the top 20 drugs by 2021 sales, and it is no surprise that products that fight COVID-19 dominated the biopharma landscape. We also talk about this weekend’s ASCO meeting and the week's other big headlines. Plus, we have bloopers! read more By Robert King The White House announced the rollout of COVID-19 vaccinations for kids under 5 could start as early as June 21, with primary care doctors playing a big role. read more By Andrea Park Fresh off the FDA’s clearance for its latest continuous glucose monitor, Abbott is already looking to one-up itself. read more By Angus Liu Back in 2013, AbbVie and Johnson & Johnson’s Imbruvica got its very first FDA go-ahead, which was for previously treated mantle cell lymphoma. Now, the company is trumpeting a trial win in newly diagnosed patients despite not showing a life-extension advantage. read more By Annalee Armstrong Merck KGaA's North American healthcare business, EMD Serono, is discontinuing a clinical trial for a med once considered a star in its oncology program, but an interim analysis has the company changing tactics. read more By Andrea Park A device that’s meant to clear out and expand the lungs may actually go too far, resulting in a potentially dangerous decrease in oxygen levels, Baxter said this week. read more By Robert King The latest Medicare Trustees report projects the Hospital Insurance Trust Fund will run out of money in 2028, two years later compared to last year's report. read more By Annalee Armstrong This could be good news, or bad news. Amylyx Pharmaceuticals has received notice from the FDA that the decision date for its amyotrophic lateral sclerosis drug has been extended. read more By Conor Hale BD will begin rolling out its latest technology for sorting and characterizing the myriad cells that make up the human body, with a speed and clarity that the company says could help identify new types of cells and the roles they play in life and disease. read more |
